Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Accounts Payables (2016 - 2026)

Cumberland Pharmaceuticals' Accounts Payables history spans 16 years, with the latest figure at $18.6 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 33.44% to $18.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.6 million, a 33.44% increase, with the full-year FY2025 number at $18.6 million, up 33.44% from a year prior.
  • Accounts Payables hit $18.6 million in Q4 2025 for Cumberland Pharmaceuticals, up from $13.8 million in the prior quarter.
  • Over the last five years, Accounts Payables for CPIX hit a ceiling of $18.6 million in Q4 2025 and a floor of $9.0 million in Q2 2021.
  • Historically, Accounts Payables has averaged $12.0 million across 5 years, with a median of $11.5 million in 2022.
  • Biggest five-year swings in Accounts Payables: fell 28.03% in 2021 and later soared 33.44% in 2025.
  • Tracing CPIX's Accounts Payables over 5 years: stood at $9.6 million in 2021, then increased by 12.22% to $10.8 million in 2022, then rose by 29.75% to $14.0 million in 2023, then fell by 0.88% to $13.9 million in 2024, then soared by 33.44% to $18.6 million in 2025.
  • Business Quant data shows Accounts Payables for CPIX at $18.6 million in Q4 2025, $13.8 million in Q3 2025, and $13.4 million in Q2 2025.